Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
|Articles|January 4, 2021
Pharmacy Times: Week of January 4 Lineup
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.
Advertisement
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week, including:
- A video interview with Jason Valent, MD, of the Cleveland Clinic, about his new research surrounding CAEL-101, a treatment for patients living with amyloid light chain amyloidosis, which was presented at the 62nd American Society of Hematology Annual Meeting & Exposition.
- A new episode of the Pharmacy Focus podcast in which we discuss steps that pharmacies can take to begin implementing COVID-19 testing with Nancy Lyons, chief pharmacist for McKesson Health Mart.
- An article that discusses how factors such as overwrought performance goals, a lack of control coupled with a flood of new graduates willing to work for low wages to pay off student debt, and dismally low reimbursement are all driving toward pharmacist burnout.
Advertisement
Related to this article
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
The once-daily device, bioequivalent to the existing prefilled syringe, gives adults with AChR antibody-positive generalized MG a second self-injection option.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Neither the lipoprotein(a) [Lp(a)]–lowering antisense oligonucleotide nor the IL-6 inhibitor cut CV events in phase 3, but patients with high Lp(a) may still bring questions to pharmacists.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Finerenone Expands MRA Options as Pharmacists Address Underrecognized HFpEF
2
Diuretics, eGFR, and Intensive BP Lowering in CKD: What to Watch
3
Researchers Target Viral Fusion for Universal Flu, HIV Vaccines
4
Finerenone in Heart Failure: Evidence and Practice a Year Later
5